Literature DB >> 34157830

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.

Sung Won Lee1,2, Jonggi Choi3, Seung Up Kim4,5, Young-Suk Lim3.   

Abstract

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

Entities:  

Keywords:  Carcinoma, Hepatocellular; Efficacy; Entecavir; Hepatitis B; Outcome; Tenofovir

Year:  2021        PMID： 34157830     DOI： 10.3350/cmh.2021.0179

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN： 2287-2728


  7 in total

1.  Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.

Authors:  Hye Yeon Chon; Sang Hoon Ahn; Yoon Jun Kim; Jung-Hwan Yoon; Jeong-Hoon Lee; Dong Hyun Sinn; Seung Up Kim
Journal:  Hepatol Int       Date:  2021-11-20       Impact factor: 6.047

2.  Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.

Authors:  Sara Jeong; Hyun Phil Shin; Ha Il Kim
Journal:  Intervirology       Date:  2021-11-03       Impact factor: 2.294

3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

Review 4.  The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.

Authors:  Jung Hwan Yu; Soon Gu Cho; Young-Joo Jin; Jin-Woo Lee
Journal:  Clin Mol Hepatol       Date:  2021-11-26

5.  Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy.

Authors:  Jae Seung Lee; Hyun Woong Lee; Tae Seop Lim; Hye Jung Shin; Hye Won Lee; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Beom Kyung Kim
Journal:  Cancers (Basel)       Date:  2021-11-23       Impact factor: 6.639

6.  A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.

Authors:  Hyung Joon Kim; Ju Hyun Kim; Jong Eun Yeon; Yeon Seok Seo; Jeong Won Jang; Yong Kyun Cho; Byoung Kuk Jang; Byung Hoon Han; Changhyeong Lee; Joon Hyeok Lee; Jung-Hwan Yoon; Kang Mo Kim; Moon Young Kim; Do Young Kim; Neung Hwa Park; Eun Young Cho; June Sung Lee; Jin-Woo Lee; In Hee Kim; Byung-Cheol Song; Byung-Seok Lee; Oh Sang Kwon
Journal:  J Korean Med Sci       Date:  2022-03-21       Impact factor: 2.153

7.  Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.

Authors:  Sang Il Choi; Yuri Cho; Moran Ki; Bo Hyun Kim; In Joon Lee; Tae Hyun Kim; Seong Hoon Kim; Young Hwan Koh; Hyun Beom Kim; Eun Kyung Hong; Chang-Min Kim; Joong-Won Park
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.